GSK Will Fold Antibody Developer Domantis Into Biopharmaceutical CEDD
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK will pay $454 mil. to acquire Domantis’ technology for unconventional administration of monoclonal antibodies.
You may also be interested in...
Follow-On Biologics Market Unfolding: Big Pharma Signals An Interest
Large pharmaceutical and biotechnology companies will start openly developing follow-on biologics once Congress passes legislation authorizing an abbreviated approval pathway, Cowen & Co. analyst Ken Cacciatore predicted
Follow-On Biologics Market Unfolding: Big Pharma Signals An Interest
Large pharmaceutical and biotechnology companies will start openly developing follow-on biologics once Congress passes legislation authorizing an abbreviated approval pathway, Cowen & Co. analyst Ken Cacciatore predicted
GSK’s Witty Looks To Biotech Model In R&D Retool; Mini Labs Will Bid For Project Funding
Planned units include five to 80 scientists, operate within the CEDDs program.